Digna Biotech regains rights for inhibitor for systemic skin sclerosis
Madrid/Barcelona – It was a rare example of a partnership between the two competing regions of Castile and Catalonia. Now the alliance between Digna Biotech and ISDIN has come to an end. Digna Biotech announced that it has reached an agreement with ISDIN to regain full rights to Disitertide peptide’s (P144) topical formulation for the therapy of skin conditions. Disitertide is a TGF-β1 (Transforming Growth Factor-Beta 1) inhibitor that has completed a Phase IIa trial for topical treatment of skin systemic sclerosis. “We will run this trial while also validating a primary end-point for a topical treatment on the disease as there is no one at present", said Digna's CEO Pablo Ortiz. In 2005 and 2006, EMA and FDA already had granted Disitertide (P144) Orphan Drug Designation to treat systemic sclerosis and localised scleroderma. Systemic sclerosis or scleroderma is a multi-systemic disorder characterised by the excessive synthesis and deposition of extracellular matrix proteins that leads to the fibrosis of skin and visceral organs. Digna Biotech is a University of Navarra’s spin-off biotech company funded by a group of investors representing some of the major corporations and financial institutions in Spain. It has its headquarters in Madrid.